Further research has demonstrated that genetically or pharmacologically inhibiting TrkB not only negates BDNF's influence on glioma synaptic activity but also significantly enhances the survival rates in xenograft models of pediatric glioblastoma and diffuse pontine glioma [44]. The gene discussed is NTRK2; the disease is central nervous system cancer.